GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (NAS:EVOK) » Definitions » Total Inventories

EVOK (Evoke Pharma) Total Inventories : $0.45 Mil (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Evoke Pharma Total Inventories?

Evoke Pharma's total inventories for the quarter that ended in Dec. 2024 was $0.45 Mil. Evoke Pharma's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $0.47 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Evoke Pharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $3.47.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Evoke Pharma's Days Inventory for the three months ended in Dec. 2024 was 362.68.

Inventory Turnover measures how fast the company turns over its inventory within a year. Evoke Pharma's Inventory Turnover for the quarter that ended in Dec. 2024 was 0.25.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Evoke Pharma's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.14.


Evoke Pharma Total Inventories Historical Data

The historical data trend for Evoke Pharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Total Inventories Chart

Evoke Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.19 0.29 0.48 0.45

Evoke Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.59 0.55 0.49 0.45

Evoke Pharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Evoke Pharma  (NAS:EVOK) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Evoke Pharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is

Net-Net Working Capital Per Share (Q: Dec. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(13.597+0.75 * 2.42+0.5 * 0.445-10.481
-0-0)/1.486
=3.47

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Evoke Pharma's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2024 )/Cost of Goods Sold (Q: Dec. 2024 )*Days in Period
=0.469/0.118*365 / 4
=362.68

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Evoke Pharma's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2024 ) / Average Total Inventories (Q: Dec. 2024 )
=0.118 / 0.469
=0.25

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Evoke Pharma's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=0.469 / 3.308
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Evoke Pharma Total Inventories Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Evoke Pharma Business Description

Traded in Other Exchanges
N/A
Address
420 Stevens Avenue, Suite 230, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Executives
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David A Gonyer director, officer: President and CEO C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Matthew J D'onofrio officer: Exec VP, Chief Bus. Officer C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Lvp Gp Iii, Llc 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Kenneth J Widder director, 10 percent owner 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Dp Vii Associates Lp 10 percent owner ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Domain Parters Vii L P 10 percent owner ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Nimesh Shah 10 percent owner 12481 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO CA 92130
Marilyn R. Carlson officer: Chief Medical Officer C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Todd C Brady director C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Scott L Glenn director
Lvpmc, Llc 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Partners Lp 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Associates, L.p. 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111